Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 15/20 | 0.86 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490256 | 1.00 | ADORA3 (0.86) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL6480063 | 0.92 | ADORA3 (1.00) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL6482773 | 0.88 | ADORA3 (0.85) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL6480914 | 0.87 | ADORA3 (0.80) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL6481456 | 0.87 | ADORA3 (0.86) | ADORA3ADORA1 | |
| SCHEMBL6480738 | 0.87 | ADORA3 (0.86) | ADORA3ADORA1 | |
| SCHEMBL6215689 | 0.86 | ADORA3 (0.87) | ADORA3ADORA1 | |
| SCHEMBL6211694 | 0.83 | ADORA3 (0.86) | ADORA3ADORA1 | |
| SCHEMBL6493678 | 0.83 | ADORA3 (0.71) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL6493731 | 0.83 | ADORA3 (0.71) | ADORA3ADORA1CYP3A4TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | ADORA3 4/4885ADORA1 14/4885CYP3A4 1940/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | ADORA3 29/4885ADORA1 89/4885CYP3A4 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.